EVE Health Group (ASX: EVE) has announced the commercial launch of Libbo erectile dysfunction (ED) treatment on the Australian market, alongside the activation of an integrated platform for men’s health.
The platform provides education and support resources to help normalise ED as a common and readily treatable medical condition, reducing stigma, addressing misconceptions, and encouraging earlier engagement with appropriate care.
It incorporates patient education, digital onboarding, and clinical assessment with referrals to hubMed and TeleDocs Clinic for medical consultation, with prescriptions issued and fulfilled through Chemist2U for direct-to-patient delivery.
The platform also provides a foundation for future product extensions and expansion into additional therapeutic indications.
End-to-End Digital Pathway
EVE’s integrated ecosystem establishes an end-to-end digital pathway encompassing assessment, consultation, prescription, and fulfilment.
It is designed to support responsible prescribing, patient engagement, and scalable national access within a regulated healthcare framework.
By combining proprietary pharmaceutical products with digital engagement and clinical networks, the company is executing a vertically-integrated commercial model intended to accelerate market entry, support patient access, and build sustainable revenue streams in men’s health.
EVE chief executive officer Damian Wood said the Libbo launch represented a key milestone in the company’s transition from manufacturing and distribution into real-world patient access.
“With our digital platform now live and prescribing, and fulfilment pathways operational, we have established the core infrastructure required to support scalable national access in men’s health,” he said.
Under-Treated Condition
ED is an often under-treated condition which affects approximately one in five adult men and up to 40% of men over the age of 40.
Despite the availability of effective therapies, many men delay seeking treatment due to stigma, inconvenience, and concerns regarding privacy.
Mr Wood said Libbo’s oral dissolving film format offered patients a discreet, convenient and fast-acting alternative to tablets, potentially lifting compliance and patient satisfaction.
“This milestone reflects the disciplined execution of our commercial strategy and positions us to build a meaningful and sustainable presence in the men’s health sector,” he added.
